Pomegra
Pershing Square led the oversubscribed round for the Neuralink-alum startup, which has logged over 100 patient procedures with its FDA-cleared thin-film brain implant.
- Precision Neuroscience closed a $250M Series D on September 24, 2026, bringing total capital raised to $430M since its 2021 founding.
- The round was co-led by Pershing Square Inc., the Ackman Oxman Institute, and an undisclosed life sciences fund, with participation from ARK Invest, Mubadala Capital, and B Capital.
- The company's Layer 7 Cortical Interface - FDA-cleared since April 2025 - has been used in over 100 patient procedures across 18 major medical institutions.
Lead
Precision Neuroscience, the New York-based brain-computer interface company founded by a former Neuralink co-founder, closed an oversubscribed $250 million Series D on September 24, 2026, at a valuation of just over $1 billion. The round was co-led by Pershing Square Inc., the Ackman Oxman Institute, and a life sciences fund that declined to be named publicly. The financing brings the company's total raised to $430 million since it was founded in 2021 - and pushes it across the unicorn threshold ahead of a planned fully implanted system clinical trial.
What Is Precision Neuroscience Building?
The company's core product is the Layer 7 Cortical Interface, a flexible thin-film array embedded with 1,024 microelectrodes. The film is thinner than a human hair and conforms to the brain's surface without penetrating tissue - a deliberate design choice that distinguishes Precision from competitors including Neuralink, which uses rigid electrodes drilled into brain matter. The device is inserted through a sub-millimeter incision and can be removed, a feature that addresses the regulatory and safety calculus that has slowed the broader BCI field.
The FDA granted 510(k) clearance for the Layer 7 device in April 2025, authorizing commercial use for recording, monitoring, and stimulating cortical activity during implantation periods of up to 30 days. That clearance enabled an expanded clinical program across 18 institutions, where over 100 patients have since undergone procedures.
Why Did Pershing Square Back a Brain-Implant Startup?
The round drew an unusually broad investor coalition. Pershing Square's involvement - historically concentrated in large-cap public equities - signals the round's perceived de-risking. The Ackman Oxman Institute, the Duquesne Family Office, and ARK Invest reflect a mix of activist capital, single-family offices, and thematic growth funds. International names including Mubadala Capital (Abu Dhabi), Mirae Asset Capital, and Korea Investment Partners broadened the base further. Hitachi Ventures, JSL Health Capital, and B Capital round out the group.
The investor mix suggests conviction that BCI is moving out of science-fiction territory and into the first stages of scalable clinical deployment. Precision's positioning - minimally invasive, reversible, surface-mounted - has historically been the safer regulatory bet compared to penetrating systems. Three years after its founding, the company has cleared FDA review and is generating clinical data at scale. For institutional capital with a five-to-ten-year horizon, that trajectory looks materially different from the early-stage BCI bets that defined the prior decade.
What Does the $430M Total Imply About the Company's Burn?
Raising $430 million over five years without a commercial product on the market is a substantial capital commitment. The 30-day implantation limit under current FDA clearance means Layer 7 remains a research and surgical tool, not a durable therapeutic device. The next regulatory milestone - a fully implanted, long-duration system - requires an entirely different trial structure and will likely need a premarket approval pathway rather than a 510(k) clearance. That process is measured in years, not quarters.
The funding will be used to advance Layer 7 through additional FDA review stages, expand the clinical program, and build manufacturing infrastructure. A clinical trial for closed-loop neuromodulation targeting treatment-resistant depression was registered in 2026, with an estimated start in August 2026. That indication - a large, underserved psychiatric population - is a more near-term commercial avenue than motor restoration, which requires longer implant durations and far more complex regulatory approval.
Competitive Context
Neuralink remains the most-watched competitor, but the comparison is increasingly strained. Neuralink's N1 device penetrates cortical tissue and targets paralyzed patients; Precision's approach is explicitly designed for broader surgical access and shorter procedures. The company's founder, Dr. Benjamin Rapoport, was part of Neuralink's original eight-person founding team before departing in 2018 over concerns about invasiveness and clinical scalability. His philosophy - that BCIs must be extremely safe to become clinical reality rather than research curiosities - has shaped Precision's entire product architecture.
Other competition exists in the electrocorticography space, but no rival has yet matched Precision's 1,024-channel density at this form factor with an active FDA clearance.
What Does Unicorn Status Mean for This Sector?
Reaching a $1 billion valuation places Precision in a small cohort of BCI companies that have attracted institutional capital at scale. The question the valuation raises implicitly is what it says about the last round. Precision's prior $102 million raise in 2024 presumably priced the company well below $1 billion; a jump of this magnitude over one round suggests either substantial clinical progress justified a re-rating or investor appetite outpaced execution milestones. The oversubscribed nature of the round - Precision did not disclose by how much the round exceeded its original target - makes the latter explanation plausible.
Outlook
Precision Neuroscience now holds FDA clearance, over $430 million in total funding, 100-plus patient procedures, and a unicorn valuation. The next 18 months will test whether those assets translate into a durable product. Advancing to long-duration implantation requires a more demanding FDA pathway, and the first truly implantable system - one patients wear at home rather than in a hospital recovery room - is still ahead. The $250 million series D buys the runway to attempt both.
